scholarly journals Efficacy of Triptolide for Children with Moderately Severe Henoch-Schönlein Purpura Nephritis Presenting with Nephrotic Range Proteinuria: A Prospective and Controlled Study in China

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Li Wu ◽  
Jianhua Mao ◽  
Xia Jin ◽  
Haidong Fu ◽  
Huijun Shen ◽  
...  

Objective.To observe the clinical efficacy of the Chinese herb, Triptolide, in children with moderately severe Henoch-Schönlein purpura nephritis (HSPN).Methods. From January 2007 to December 2011, 56 HSPN children manifested by nephrotic range proteinuria with normal kidney function and<50% crescents or sclerosing lesions on biopsy were hospitalized in the Children’s Hospital of Zhejiang University School of Medicine. They were divided into two groups: the treatment group (Triptolide at a dosage of 1 mg/kg·d, combined with prednisone at a dosage of 2 mg/kg·d, within a course of medium-to-long-term therapy of 6 to 9 months) and the control group (; prednisone alone, with the same procedure).Results.Short-term remission was observed in 95% of patients from treatment group and in 72% of patients from control group, respectively. There was a significant difference between both groups () for short-term effects. Meanwhile, no significant difference, as proteinuria, hematuria, hypertension, and decreased eGFR, was observed between the two groups in long-term followup (). The Kaplan-Meier plot analysis also revealed no significant difference ().Conclusion.Triptolide is effective in relieving short-term symptoms for moderately severe HSPN children, though its long-term effects need to be observed further.

2018 ◽  
Vol 34 (4) ◽  
pp. 663-670 ◽  
Author(s):  
Xiao-qing Yang ◽  
Yan-jie Huang ◽  
Wen-sheng Zhai ◽  
Xian-qing Ren ◽  
Qing-yin Guo ◽  
...  

2007 ◽  
Vol 22 (10) ◽  
pp. 1717-1722 ◽  
Author(s):  
Mohan Shenoy ◽  
Mark G. Bradbury ◽  
Malcolm A. Lewis ◽  
Nicholas J. A. Webb

2021 ◽  
Vol 9 ◽  
Author(s):  
Meiqiu Wang ◽  
Ren Wang ◽  
Xu He ◽  
Pei Zhang ◽  
Qianhuining Kuang ◽  
...  

Introduction: Henoch–Schönlein purpura nephritis (HSPN) and IgA nephropathy (IgAN) bear similarities in some aspects. The histological classification of HSPN was built on the International Study of Kidney Disease in Children (ISKDC) criteria, while IgAN was established on the 2016 Oxford classification (MEST-C scores). The purpose of this paper was to discuss the predictive value of the ISKDC classification and MEST-C scores in children with HSPN.Methods: We performed a retrospective study of 877 children with HSPN in a single center between 2001 and 2019. The primary outcome was defined as chronic kidney disease—estimated glomerular filtration rate (eGFR) &lt;90 ml/min/1.73 m2.Results: During the follow-up period of 23.3 (10.9–47.9) months, 51 (5.8%) patients reached the primary outcome. As revealed in a Kaplan–Meier plot, segmental glomerulosclerosis (S) (P &lt; 0.001) and tubular atrophy/interstitial fibrosis (T) (P &lt; 0.001) significantly predict poor renal outcome. Other Oxford lesions and the ISKDC classification, however, did not show a significant difference in a worse outcome. In a multivariate Cox model adjusted for pathological and clinical factors, eGFR [hazard ratio (HR) = 2.831, 95% confidence interval (95% CI) = 1.359–5.896], S lesion (HR = 3.936, 95% CI = 2.078–7.457), and T lesion (HR = 4.002, 95% CI = 1.733–9.242) were independent risk factors for the renal outcome.Conclusion: This series constitutes the largest series reported so far in the literature of such patients. According to our findings, S and T of the Oxford classification, which are ignored by the ISKDC classification, could be applied to predict the renal prognosis of children with HSPN.


2019 ◽  
Vol 6 (4) ◽  
pp. 221-225
Author(s):  
K. Chaika ◽  
N. Makieieva

PROINFLAMMATORY CYTOKINES IL-8 AND TNFα IN HENOCH-SCHONLEIN PURPURA IN CHILDREN Chaika K., Makieieva N. Henoch-Schonlein purpura (HSP) belongs to a group of systemic vasculitis with predominant damage to small caliber vessels (EULAR/Pres, 2006). Difficulties in diagnosis in the early stages and the likelihood of developing complications leaves HSP in the top of the current issues of pediatrics today. Kidney damage is observed in 20-50% of patients with HSP and leads to complications. In recent years, the question of prognostic markers of progression of HSP remains open. The study involved examination of total of 83 HSP patients aged between 2 and 17, divided into two groups: patients with HSP without nephrotic syndrome (HSPWN, n = 58.35 of which were boys and 23 - girls) and a group of patients with HSP with renal syndrome (HSPN, n = 25.14 of them boys and 11 girls) in acute and remission periods. The Kraskal-Wallis analysis recorded a highly statistically significant H criterion for IL-8 in the acute period (H = 17.421, p = 0.0002) and the remission period (H = 13.035, p = 0.0015). IL-8 levels in both groups of patients with HSP WN and HSPN were significantly higher in the acute period than in the control group, and the difference was statistically significant (p = 0.0004 and p = 0.0002, respectively). No significant difference was found between the medians in both periods regarding TNF-α level (H = 4.136, p = 0.1264; H = 0.133, p = 0.9356). In the group HSPN in the acute phase, a high IL-8 level in serum has been recorded compared to the group HSPWN. There was no significant difference in TNF-α level in both groups. Keywords: children, Henoch-Schonlein purpura, Ig-A vasculitis, nephritis.   Абстракт ПРОЗАПАЛЬНІ ЦИТОКІНИ IL-8 ТА TNFα У ДІТЕЙ ІЗ ПУРПУРОЮ ШЕНЛЯЙН-ГЕНОХА Чайка Х., Макєєва H. Пурпура Шенлейна-Геноха (ПШГ) відноситься до групи системних васкулітів з переважним пошкодженням судин малого калібру (EULAR / Pres, 2006). Труднощі в діагностиці на ранніх стадіях та ймовірність розвитку ускладнень залишають ПШГ в числі актуальних проблем педіатрії сьогодні. Ураження нирок спостерігається у 20-50% пацієнтів з ПШГ і призводить до ускладнень. В останні роки питання прогностичних маркерів прогресування ПШГ залишається відкритим. Обстежено 83 пацієнта з ПШГ у віці від 2 до 17 років, які були розділені на дві групи: пацієнти з ПШГ без нефротичного синдрому (ПШГБН, n = 58, 35 з яких були хлопчики і 23 - дівчатка) і група пацієнтів із ПШГ з нирковим синдромом (ПШГН, n = 25, з них 14 хлопчиків і 11 дівчаток) в періоди загострення і ремісії. Аналіз Краскала-Уолліса зареєстрував високий статистично значимий критерій H для IL-8 в гострому періоді (H = 17,421, p = 0,0002) і періоді ремісії (H = 13,035, p = 0,0015). Рівні IL-8 в обох групах пацієнтів з ПШГБН і ПШГН були значно вище в гострому періоді, ніж у контрольній групі, і різниця була статистично значущою (p = 0,0004 і p = 0,0002, відповідно). Не було виявлено суттєвих відмінностей між медіанами в обидва періоди щодо рівня TNF-α (H = 4,136, p = 0,1264; H = 0,133, p = 0,9356). У групі ПШГН в гострій фазі був зафіксований високий рівень IL-8 в сироватці в порівнянні з групою ПШГБН. Не було значної різниці в рівні TNF-α в обох групах. Ключові слова: Ig-A васкуліт, діти, пурпура Шенлейна-Геноха, нефрит.   Абстракт ПРОВОСПАЛИТЕЛЬНЫЕ ЦИТОКИНЫ IL-8 И TNFα У ДЕТЕЙ С ПУРПУРОЙ ШЕНЛЕЙН-ГЕНОХА Чайка K., Макеева H. Пурпура Шенлейн-Геноха (ПШГ) относится к группе системных васкулитов с преимущественным повреждением сосудов малого калибра (EULAR / Pres, 2006). Трудности в диагностике на ранних стадиях и вероятность развития осложнений оставляют ПШГ в числе актуальных проблем педиатрии сегодня. Поражение почек наблюдается у 20-50% пациентов с ПШГ и приводит к осложнениям. В последние годы вопрос о прогностических маркерах прогрессирования ПШГ остается открытым. Обследовано 83 пациента с ПШГ в возрасте от 2 до 17 лет, которые были разделены на две группы: пациенты с ПШГ без нефротического синдрома (ПШГБН, n = 58, 35 из которых были мальчики и 23 - девочки) и группа пациенты с ПШГ с почечным синдромом (ПШГН, n = 25, из них 14 мальчиков и 11 девочек) в периоды обострения и ремиссии. Анализ Краскала-Уоллиса зарегистрировал высокий статистически значимый критерий H для IL-8 в остром периоде (H = 17,421, p = 0,0002) и периоде ремиссии (H = 13,035, p= 0,0015). Уровни IL-8 в обеих группах пациентов с ПШГБН и ПШГН были значительно выше в остром периоде, чем в контрольной группе, и разница была статистически значимой (p = 0,0004 и p = 0,0002, соответственно). Не было обнаружено существенных различий между медианами в оба периода в отношении уровня TNF-α (H = 4,136, p = 0,1264; H = 0,133, p = 0,9356). В группе ПШГН в острой фазе был зафиксирован высокий уровень IL-8 в сыворотке по сравнению с группой ПШГБН. Не было значительного различия в уровне TNF-α в обеих группах. Ключевые слова: Ig-A васкулит, дети,пурпура Шенлейн-Геноха, нефрит.  


2021 ◽  
Vol 38 (1) ◽  
Author(s):  
Chao Li ◽  
Zhi-bin Wang

Objectives: To investigate the curative effect of Compound Glycyrrhizin Tablets in the adjuvant treatment of simplex Henoch-Schonlein purpura and its influence in improving immune function. Methods: In this retrospective study design was used in this study. Eighty newly diagnosed patients with purpura simplex who visited the outpatient department of Baoding First Central Hospital from June 2017 to February 2020 were included. They were randomly divided into treatment group and control group. The two groups were provided with the same conventional comprehensive treatment. Patients in the treatment group received oral administration of Compound Glycyrrhizin Tablets on the basis of conventional treatment. The clinical efficacy of the treatment group and the control group were compared according to the time and effect of purpura regression, followed by the comparison of changes of T cell subsets before and after treatment. Results: The total effective rate of the treatment group was 92.5%, which was higher than that of the control group (77.5%) (P < 0.05). The purpura subsidence time of effective patients in treatment group was shorter than that in control group (P < 0.05). There was no significant difference in lymphocyte subsets between the treatment group and the control group before treatment. After treatment, the proportion of CD4+ cells and CD4+/CD8+ cells in the treatment group were obviously higher than that in the control group, and the count of CD8+ cells was evidently lower than that in the control group (P < 0.05). Conclusions: Compound Glycyrrhizin is effective in the adjuvant treatment of simplex Henoch-Schonlein purpura without obvious adverse reactions, which is valuable for clinical application as an adjuvant. doi: https://doi.org/10.12669/pjms.38.1.4609 How to cite this:Li C, Wang Z. Clinical application of compound Glycyrrhizin tablets in the treatment of patients with Simplex Henoch-Schonlein Purpura and its effect on immune function. Pak J Med Sci. 2022;38(1):---------. doi: https://doi.org/10.12669/pjms.38.1.4609 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


2014 ◽  
Vol 104 (8) ◽  
pp. 843-848 ◽  
Author(s):  
Elena Tudorache ◽  
Christine Azema ◽  
Julien Hogan ◽  
Hala Wannous ◽  
Bilal Aoun ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document